Introducing Estrogen Metabolism as the Main Target of Wedelia chinensis in Prostate Cancer Cells

Document Type : Original paper

Authors

1 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Traditional Medicine and Materia Medica Research Center and Department of Traditional Medicine, School of Traditional Medicine, Shahid, Beheshti University of Medical Sciences, Tehran, Iran.

3 Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Background and objectives: Investigations indicate that Wedelia chinensis extract increases efficacy of prostate cancer treatment. In the present study, the differentially expressed genes (DEGs) of prostate cancer cell line 22RV1 in the presence of W. chinensis extract derived from Gene Expression Omnibus (GEO) were evaluated by gene ontology and pathway analysis. Methods: Gene expression profiles of GSE100224 were analyzed by GEO2R. The significant DEGs were assessed via action map analysis. The related biological terms were identified for the significant DEGS. The highlighted dysregulated genes and pathways were discussed. Results: Seventy significant DEGs including 49 up-regulated genes and 21 down-regulated ones were assessed by inhibition, activation, expression, and binding actions. Cytochrome P450 and PTGS2 were highlighted as the crucial DEGs. Estrogen metabolism was pointed as the main targeted pathway.  Conclusion: Findings indicated that “estrogen metabolism” and UGT1A1, MAOA, PTSG2, and cytochrome P450 in the 22RV1 cells were the main targeted pathway and genes by W. chinensis .

Keywords

Main Subjects

References

  • Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022; 10: 1–18.
  • Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019; 70: 479– 499.
  • Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014; 74(19): 5631–5643.
  • Xiong RG, Huang SY, Wu SX, Zhou DD, Yang ZJ, Saimaiti A, Zhao CN, Shang A, Zhang YJ, Gan RY, Li Anticancer effects and mechanisms of berberine from medicinal herbs: an update review. Molecules. 2022; 27(14): 1–19.
  • Tsai CH, Tzeng SF, Hsieh SC, Yang YC, Hsiao YW, Tsai MH, Hsiao A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. Sci Rep. 2017; 7(1): 1–14.
  • Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, Hsieh SC, Hsiao Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 2009; 15(17): 5435–5444.
  • Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res. 2004; 10(10): 3237–3248.
  • Zhang L, Zheng W, Tang R, Wang N, Zhang W, Jiang X. Gene regulation with carbon-based siRNA conjugates for cancer therapy. Biomaterials. 2016; 104: 269–278.
  • Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem. 2003; 88(2): 363–371.
  • Valencia A, Hidalgo M. Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. Genome Med. 2012; 4(7): 1–17.
  • Sun J, Li S, Wang F, Fan C, Wang J. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis. BMC Med Genet. 2019; 20(1): 1–9.
  • Fan S, Liang Z, Gao Z, Pan Z, Han S, Liu X, Zhao C, Yang W, Pan Z, Feng Identification of the key genes and pathways in prostate cancer. Oncol Lett. 2018; 16(5): 6663–6669.
  • He S, Shi J, Mao J, Luo X, Liu W, Liu R, Yang F. The expression of miR-375 in prostate cancer: a study based on GEO, TCGA data and bioinformatics analysis. Pathol Res Pract. 2019; Article ID 152375.
  • Gan BL, Zhang LJ, Gao L, Ma FC, He RQ, Chen G, Ma J, Zhong JC, Hu Downregulation of miR-224-5p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses. Oncol Rep. 2018; 40(6): 3171–3188.
  • Azodi MZ, Peyvandi H, Rostami-Nejad M, Safaei A, Rostami K, Vafaee R, Heidari M, Hosseini M, Zali Protein-protein interaction network of celiac disease. Gastroenterol Hepatol Bed Bench. 2016; 9(4): 268–277.
  • Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, Mueller SC, von Ruecker Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer. 2008; 122(1): 138–143.
  • Chen TC, Sakaki T, Yamamoto K, Kittaka A. The roles of cytochrome P450 enzymes in prostate cancer development and treatment. Anticancer Res. 2012; 32(1): 291–298.
  • Allam RM, Al-Abd AM, Khedr A, Sharaf OA, Nofal SM, Khalifa AE, Mosli HA, Abdel-Naim Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett. 2018; 291: 77–85.
  • Lin YC, Chang YT, Campbell M, Lin TP, Pan CC, Lee HC, Shih JC, Chang MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci Rep. 2017; 7(1): 1–17.
  • Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, Neamati Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. Br J Cancer. 2015; 113(2): 242–251.
  • Liu D, Yu Q, Ning Q, Liu Z, Song J. The relationship between UGT1A1 gene & various diseases and prevention strategies. Drug Metab Rev. 2022; 54(1): 1–21.
  • Karatzas A, Giannatou E, Tzortzis V, Gravas S, Aravantinos E, Moutzouris G, Melekos M, Tsezou Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol. 2010; 34(3): 345–349.
Research Journal of Pharmacognosy
Volume 10, Issue 4
October 2023
Pages 9-15

Files

Share

How to cite

Statistics